Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
Source:http://linkedlifedata.com/resource/pubmed/id/18398152
J. Clin. Oncol.
2008
Apr
10
26
11
1871-8
